Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer (NSCLC). In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs publi...

全面介紹

Na minha lista:
書目詳細資料
發表在:Transl Lung Cancer Res
Main Authors: Gao, Hui, Ding, Xin, Wei, Dong, Cheng, Peng, Su, Xiaomei, Liu, Huanyi, Aziz, Fahad, Wang, Daoyuan, Zhang, Tao
格式: Artigo
語言:Inglês
出版: Pioneer Bioscience Publishing Company 2012
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367576/
https://ncbi.nlm.nih.gov/pubmed/25806169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2012.06.01
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍